Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2777044 | 1.00 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL15764103 | 1.00 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL15764139 | 1.00 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18296369 | 0.98 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL82007 | 0.95 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL81591 | 0.91 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1KMT2AGRIN2BMBTD1 | |
| SCHEMBL82890 | 0.88 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1KMT2AGRIN2BMBTD1 | |
| SCHEMBL12082201 | 0.86 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1HRH3MBTD1ADRB1 | |
| SCHEMBL81367 | 0.85 | HTR6 (0.58) | L3MBTL3L3MBTL1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22940344 | 0.84 | KMT2A (0.64) | L3MBTL3L3MBTL1KMT2AGRIN2BADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-3480186-B1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3459936-B1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-04-27 | — | — | EP | disclosed |
| EP-3480186-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-05-08 | — | — | EP | disclosed |
| EP-3459936-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-03-27 | — | — | EP | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9376424-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20140323490-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8809347-B2 | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8741898-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130281468-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2013-10-24 | — | — | US | disclosed |
| US-8492373-B2 | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | L3MBTL3 1989/4885L3MBTL1 3725/4885CYP3A4 4138/4885 |
| US-20130281468-A1 | BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB2 | L3MBTL3 2110/4885L3MBTL1 2206/4885CYP3A4 1896/4885 |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | L3MBTL3 3429/4885L3MBTL1 2596/4885CYP3A4 4623/4885 |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, FAAH2 | L3MBTL3 4272/4885L3MBTL1 2896/4885CYP3A4 2936/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | L3MBTL3 4681/4885L3MBTL1 4537/4885CYP3A4 713/4885 |
| US-20140323490-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | L3MBTL3 2154/4885L3MBTL1 2161/4885CYP3A4 3592/4885 |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | L3MBTL3 2570/4885L3MBTL1 3671/4885CYP3A4 4142/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | L3MBTL3 3628/4885L3MBTL1 2790/4885CYP3A4 4662/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | L3MBTL3 3628/4885L3MBTL1 2790/4885CYP3A4 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.